Cupps Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cupps Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-5,602	Closed	-$590K	–	186
2015 Q3	$590K	Sell	5,602 -47,456	-89%	-$6.34M	0.08%	127
2015 Q2	$7.26M	Buy	53,058 +28,012	+112%	+$3.47M	0.7%	58
2015 Q1	$3.12M	Sell	25,046 -16,927	-40%	-$1.79M	0.28%	97
2014 Q4	$3.79M	Buy	41,973 +21,713	+107%	+$1.81M	0.34%	86
2014 Q3	$1.46M	Buy	20,260 +9,665	+91%	+$635K	0.14%	128
2014 Q2	$659K	Sell	10,595 -19,666	-65%	-$1.19M	0.05%	148
2014 Q1	$2.06M	Buy	+30,261	New	+$2.23M	0.16%	126

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cupps Capital Management's BMRN Position: Q4 2015 in Review

Cupps Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 5,602 shares — an estimated $590K sold.

Cupps Capital Management first reported a position in BMRN in Q1 2014 and held it in 7 quarters. The position peaked at $7.26M in Q2 2015. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Cupps Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Cupps Capital Management sold 5,602 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $590K.
Cupps Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Cupps Capital Management's BioMarin Pharmaceuticals position peaked at $7.26M in Q2 2015.
388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Cupps Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.